TNFSF13 and rheumatoid arthritis: Inhibition of APRIL could lead to improved outcomes in RA by reducing the local autoantibody production and modulating B cell activity in synovial tissues. This therapeutic strategy holds promise for decreasing joint inflammation and damage.